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Introduction
Pulmonary hypertension (PH) is a devastating, progressive 
disease with increasingly debilitating symptoms and usually 
shortened overall life expectancy due to narrowing of the 
pulmonary vasculature and consecutive right heart failure 
(RHF). PH is defined by an increase in mean pulmonary 
arterial pressure (mPAP) >25 mmHg at rest assessed by 
right heart catheterization (1,2) or by echocardiography with 
a right ventricular systolic pressure (RVSP) >35 mmHg, 
absence of pulmonary stenosis and acute RHF, and usually 
accompanied by shortness of breath, fatigue, peripheral 
edema and other cardiovascular symptoms (3). PH can be 
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caused by a multitude of conditions and co-morbidities 
highly prevalent in low- and middle-income countries 
(LMICs) and may complicate the majority of respiratory 
and cardiovascular diseases leading to excess morbidity and 
mortality in these multi-morbid patients. 
Figure 1 illustrates the updated clinical classification 
of PH with emphasis on risk factors and co-morbidities 
prevalent in LMICs according to the 6th World Symposium 
on Pulmonary Hypertension (WSPH) task force published 
by Simonneau et al. (4). Group 1 (pulmonary arterial 
hypertension, PAH) includes idiopathic, heritable, and 
drug-induced PAH and is associated with conditions such 
as human immunodeficiency virus (HIV), schistosomiasis, 
and congenital heart disease (CHD). Group 2 includes 
PH due to left heart disease (PH-LHD) related to systolic 
dysfunction, diastolic dysfunction, valvular disease, or a 
combination of these conditions. PH resulting from lung 
diseases and hypoxemia, or both, comprises Group 3 PH-
LD and is associated with chronic obstructive pulmonary 
disease (COPD), interstitial lung disease, pulmonary 
diseases with a mixed restrictive and obstructive pattern. 
Post tuberculosis (TB) bronchiectasis and fibrotic-cavitary 
pulmonary disease is another major risk factor for the 
development of Group 3 PH. Chronic thromboembolic 
pulmonary hypertension (CTEPH) corresponds to Group 
4, and Group 5 includes a heterogeneous group of disorders 
that may cause PH by unclear or multiple mechanisms, or 
both (1,2,4,5).
In the last decades, significant progresses in the diagnosis 
and management of PH have gradually moved this 
condition from an orphan disease to major global health 
problem (6). It is estimated that about 80% of the global 
burden of the disease is in LMICs where PH is known to 
be highly associated with CHD, rheumatic heart disease, 
schistosomiasis and HIV (6,7). Despite these risk factors 
for PH, left heart disease (LHD) still remains the most 
common etiology for PH in both LMICs and high-income 
countries (HICs) (8-10). Contrary to what is observed in 
HICs where PH is predominant in the elderly above the 
ages of 65 years, it is very common in younger individuals 
Figure 1 The figure illustrates the updated clinical classification of PH with emphasis on risk factors and co-morbidities prevalent in LMICs 
according to the 6th WSPH task force published by Simonneau et al. (4). PH, pulmonary hypertension; LMICs, low- and middle-income 
countries; WSPH, World Symposium on Pulmonary Hypertension; LVEF, left ventricular ejection fraction; HIV, human immunodeficiency 
virus; COPD, chronic obstructive pulmonary disease.
Group 1
Pulmonary Arterial Hypertension (PAH)
1.1 Idiopathic PAH
1.2 Heritable PAH
1.3 Drug- and toxin-induced PAH (table 3)
1.4 PAH associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.5 PAH long-term responders to calcium channel blockers
1.6 PAH with overt features of venous/capillaries (PVOD/PCH) involvement
1.7 Persistent PH of the newborn syndrome
Group 3
PH due to lung disease and/or hypoxia (PH-LD)
3.1 Obstructive lung disease (COPD) 
3.2 Restrictive lung disease
3.3 Other lung disease with mixed restrictive/obstructive pattern*
3.4 Hypoxia without lung disease
3.5 Developmental lung disorders
*e.g. post-tuberculosis bronchiectasis and fibro-
cavitarypulmonary disease
Group 4
PH due to pulmonary artery obstructions
4.1 Chronic thromboembolic PH (CTEPH)*
4.2 Other pulmonary arteryobstructions
*potentially in patients with HIV tuberculosis co-infection in 
septic hypercoagulable state at increased risk for CTEPH 
Group 5
PH with unclear and/or multifactorial mechanisms
5.1 Haematological disorders
5.2 Systemic and metabolic disorders
5.3 Others
5.4 Complex congenital heart disease
Group 2
PH due to left heart disease (PH-LHD)
2.1 PH due to heart failure with preserved LVEF
2.2 PH due to heart failure with reduced LVEF
2.3 Valvular heart disease
2.4 Congenital/acquired cardiovascular conditions leading to post-capillary PH
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Figure 2 Estimated global distribution of most forms of PH. LHDs are the most common underlying cause of PH on all continents, 
followed by lung disease. Not shown in this figure is schistosomiasis associated PH which is most commonly found in South America, while 
data from other regions is lacking. Adapted from Hoeper et al. (7). PH, pulmonary hypertension; LHD, left heart disease.
in LMICs (7).
LMICs are known to have limited resources for the 
diagnosis and treatment of several diseases including PH. 
PH has debilitating symptoms and if left untreated, it has 
poor survival and reduced life expectancy (11,12). Another 
well-known factor that has accounted for high mortality 
rates in sub-Saharan Africa (SSA) is the fact that patients in 
these settings usually present to the hospital at late stages 
of the disease (WHO functional class III and IV) (3,8,13). 
This is mainly due to two reasons: (I) accessibility to 
health care, and (II) non-specific nature of PH symptoms 
such as shortness of breath and fatigue. In addition to the 
above, there is lack of adequate diagnostic tools at primary 
care, with most cases in SSA and other LMICs are usually 
misdiagnosed as heart failure, other cardio-respiratory 
conditions, or even TB (12,14).
Recent advances have been made in the development 
of effective treatments, especially for PAH and CTEPH 
(15,16). Vasodilators, endothelin receptor antagonists, 
phosphodiesterase (PDE) inhibitors (e.g., sildenafil) and 
high-dose calcium channel blockers (e.g., amlodipine) are 
the most commonly prescribed drug, with the latter two 
also available in SSA and other LIMC (17). CTEPH is a 
potentially curable disease when treated with pulmonary 
thromboendarterectomy (PTE).
Nonetheless of all advances in the management of PH, 
there is still limited data on the epidemiology of PH in 
LMICs. The pan African pulmonary hypertension cohort 
(PAPUCO) study provides the most comprehensive data 
on the prevalence, etiologies, classification, morbidity and 
mortality of PH on the African continent (3,17).
Epidemiology of PH
The exact global burden of PH remains unknows, and 
most likely largely underestimated due to the above-
mentioned circumstances in LMICs. It is estimated 
that about 80% of patients with PH live in LMICs and 
disproportionately affecting younger people at an age 
<65 years (7). Overall, LHD still remains the dominant 
risk factor for PH (PH-LHD), followed by chronic lung 
disease and hypoxia (PH-LD), while PAH remains rare 
even in high HIV prevalent settings in SSA (Figure 2), 
where also untreated streptococcal infections leading to 
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rheumatic fever rheumatic heart disease and sickle cell 
disease are endemic (3,6,7,18). As of 2015, it was estimated 
that up to 50–70 million individuals were affected by PH 
globally, which is expected to rise as global population 
and life expectancy increases (7,19). About 30 million 
individuals are estimated to have heart failure associated 
PH, 25 million estimated to have COPD associated PH, 
150,000 individuals estimated to have HIV-associated PH 
(HIV-PH), 3.75 million individuals estimated to suffer 
rheumatic heart disease associated PH, and 2 million 
individuals estimated to have sickle cell disease associated 
PH (7).
Mortality of PH is high in both LMICs and HICs 
(20-24). A 5-year mortality rate of 26% was recorded 
in  a  Swiss  cohort  of  PAH, CTEPH and PH-LD 
patients (11). Similar mortality rates have been recorded 
in SSA in a short observational period of only 6 months 
(3,8). The PAPUCO study described the causes, treatment 
and outcome of PH in Africa in both adult and pediatric 
populations (3). According to this continent wide study, 
69% of PH-LHD, 16% due to PAH, 11% of PH-LD, 
2% due to CTEPH, and 2% due to multifactorial/unclear 
mechanism (Figure 3).
In PAPUCO, we found a high 6-month mortality 
of 21% in adults associated with functional limitations 
at time of presentation. To our knowledge, PAPUCO 
remains the only study that has classified PH according to 
the current guidelines. In a recent review on PH in Africa, 
findings showed that the prevalence of PH varies widely 
across different population: 9.8% in patients presenting 
with cardio-respiratory complaints, 10% in HIV-infected 
patients, 32.9% in patients with heart failure, 23.2% 
in patients on hemodialysis, 12.9% in patients with 
RHD, 37% to 53% in patients with sickle cell disease 
(9,22,25,26).
The high prevalence of PH-LHD in LMICs is expected 
due to a higher prevalence of uncontrolled hypertension 
which is also a principal cause of heart failure according to 
the sub-Saharan acute heart failure (THESUS-HF) study, 
a study conducted in nine African countries (27). Lung 
disease and hypoxia is known to be the second leading cause 
of PH after LHD. Studies from SSA suggest a relationship 
Figure 3 Subgroup classification of adult cases of the PAPUCO study according to contemporary WHO criteria revealed that 16% of 
patients as Group 1 (PAH), 69% as Group 2 (PH-LHD), 11% as Group 3 (PH-LD ), 2% as Group 4 (CTEPH), and 2% as Group 5 (PH 
with unclear/multifactorial mechanism). PAPUCO, pan African pulmonary hypertension cohort; PH, pulmonary hypertension; PAH, 
pulmonary arterial hypertension; PH-LHD, PH due to left heart disease; PH-LD, PH due to lung disease and/or hypoxia; CTEPH, chronic 
thromboembolic pulmonary hypertension.
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between indoor exposure to smoke from burning biomass 
and PH, but the actual risk has not been fully explored 
(3,8). A study from Egypt reported a prevalence of 63% 
among patients with COPD (28). Another study in Libya 
showed a prevalence of 8% among patients with pulmonary 
disease (29). The high prevalence of COPD across all age 
groups may be linked to occupation risk such as mining, 
direct and passive smoking, urban pollution, and indoor 
pollution from domestic fires for cooking and heating, 
as well as to endemic levels of TB leading to post-TB 
bronchiectasis and fibro-cavitary pulmonary disease with 
COPD type pattern (TB obstructive pulmonary disease, 
TOPD) (3). Ahmed et al. published a case series of 14 
Sudanese patients with PH after successful completion of 
treatment for TB. The group reported further different 
severity and grades of PH with a median time from 
completion of treatment to TB to diagnosis of PH of nine 
years, suggesting an underestimated burden of persistent 
morbidity in TB globally in patients defined as “cured” by 
microbiologic means (30). 
A South African study identified PH as one of the 
commonest causes of death accounting for 31% of total 
cardiovascular deaths (31). A study in Cameroon reported 
6-month mortality rates of 28% (8). The reasons for high 
mortality rates in LMICs are lack of access to health care, 
infrastructure and equipment to diagnose PH within the 
health care system, and availability of specific treatment 
for PH. In Mexico a study involving patients with CTEPH 
reported that only one patient out of 50 underwent 
pulmonary endarterectomy despite many patients being 
eligible. Reasons identified were lack of insurance coverage 
for patients eligible for surgery and lack of infrastructure 
for post-operative care after the procedure (32). 
People living with HIV have an increased risk of 
developing PH. With HIV being more prevalent in LMICs 
and endemic in SSA it is expected that there will be a higher 
burden of PAH in this region. To date, no systematic 
studies have been carried out to report the incidence 
of PH among HIV patients in SSA. On a global scale, 
the prevalence of PH in HIV-infected individuals varies 
between 0.5% and 5.0% with HIV being recognized as an 
independent risk factor for the development of PH. The 
prevalence of HIV-PH in developed countries in the era 
of combined antiretroviral therapy (cART) is 0.5%, while 
5.5% of patients with no symptoms of PH may be at risk 
for PH; 1,000-fold higher than in the general population. 
Studies conducted in Africa found evidence of PH by 
echocardiographic measurements in 0.6–5% of HIV patients 
in Nigeria, Burkina Faso, and Zimbabwe. Estimated survival 
rates in developed countries in the pre-cART era were 
about 70% at 1 year and 50% at 3 years compared with 
about 90% at 1 year and 70% at 3 years after the advent of 
cART. Even though these data seem convincing a direct 
benefit of cART on the incidence and survival of HIV-PH 
could not be demonstrated. Combination antiretroviral 
therapy alone without specific treatment for PH does not 
result in an improved cardiac function. Also, no association 
between HIV-PH and CD4 count, viral load, or stage of 
disease could be identified. Thus, the prevalence of PH 
among HIV patients in the African context varies widely. 
Studies also report a slight female predominance (33). It 
would be relevant to investigate in a large cohort study 
the true incidence and factors that affect the occurrence of 
HIV-PH.
Schistosomiasis has been identified to be one of the 
major causes of PH as a result of host immune response 
to the parasite antigen. Worldwide, 200 million people 
are infected by Schistosomiasis, with majority of these 
living in LMICs especially in Africa, parts of Asia and 
South America. About 1% of people with schistosomiasis 
develop PH (34,35). Sickle cell disease is another 
identified risk factor that has been associated with PH. In 
Nigeria, a case-control study among patients with sickle 
cell disease revealed a prevalence of 22.9% in patients 
with hemoglobin SS as compared to 2.3% in patients 
with hemoglobin AA (36). In another echocardiography 
study, PH was detected in 23.9% of adults with sickle cell 
disease (37), with reported higher mortality in these group 
of patients (38).
Pathogenesis of PH
The pathogenesis of PH is different for every clinical 
WHO group and the underlying risk factors, diseases and 
co-morbidities contribute to pathophysiological changes in 
the heart, lungs and pulmonary arteries. PH presents as a 
clinical syndrome characterized by shortness of breath and 
loss of exercise capacity that is related to increased PAP and 
pulmonary vascular resistance (PVR), with vasoconstriction, 
proliferation, thrombosis, and re-modelling of the 
pulmonary vessels (4). Vasoconstriction occurs in early 
disease, followed by micro-thrombotic embolism. Re-
modelling of the small and middle size pulmonary arteries 
is the critical factor leading to disease progression with 
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increasing morbidity and mortality. 
Management PH in LMICs
A number of guidelines exist for the diagnosis and treatment 
of PH, but the joined European Society of Cardiology 
(ESC) and the European Respiratory Society (ERS) 
guidelines for the diagnosis and treatment of PH are the 
most comprehensively used, regularly updated and widely 
recognized in PH. The 2015 guidelines provide some 
changes from the 2009 guidelines, including but not limited 
to simplified content structure, new parameters for the 
hemodynamic definition of post-capillary PH, the inclusion 
PVR in the hemodynamic definition of PAH, and updated 
diagnostic and treatment algorithms (1). With limitations 
in clinical and hemodynamic characterization of PH based 
on a resting value of mean pulmonary artery pressure alone, 
recent suggestions have been made to include a PVR ≥3 
Wood Units in the definition of all forms of pre-capillary 
PH and a cut-off point of mPAP ≥20 mmHg (1,4).
According to ESC/ERS guidelines, the standard 
procedures in a patient with suspected PH are complex 
investigations inclusive, but not limited to doppler 
echocardiography (doppler echo), pulmonary angiography, 
right heart and left heart catheterization, high-resolution 
computed tomography, lung function testing, and 
ventilation/perfusion scan (V/Q scan) (1,2). The above 
diagnostic techniques require high skilled operational 
personnel, continuous technical maintenance or even 
radionucleotides, mostly not readily available in resource 
limited settings, or only available in large urban centers 
such as university hospitals. 
Doppler echo has been shown to be highly specific and 
sensitive in the detection of PH, if in the hands of a well-
trained cardiologist or technician (39). In the context 
of the previously described limitations in LMICs and 
with PH-LHD being the most frequent form of PH, our 
group recently provided a simplified diagnostic algorithm 
(Figure 4) for the diagnosis of PH-LHD in resource-limited 
settings (40). This four-step diagnostic approach includes 
in step (I) a clinical evaluation to detect predisposing 
conditions for PH-LHD such as hypertension, and signs 
including pitting edema, raised jugular venous pressure, 
nail clubbing; step (II) assessment with chest X-ray and 
electrocardiogram to uncover the presence of PH-LHD 
such as cardiomegaly with enlarged right atrium and 
pulmonary arteries, prominent pulmonary outflow tract, 
and pruning of peripheral pulmonary vessels on chest 
X-ray, and sinus tachycardia with right-axis deviation, right 
atrial enlargement, ventricular hypertrophy and strain, and 
broadening of the QRS complex on electrocardiogram; 
step (III) confirmation of the presence of PH-LHD using 
doppler echo, and step (IV) investigation of differential 
etiologies and classification of the clinical WHO group 
of PH.
Despite advances in treatment of various forms of PH, 
specific PH drugs are still largely unavailable in LMICs. 
Specific drugs for PH such as vasodilators, endothelin 
receptor antagonists, phosphodiesterase PDE inhibitors 
(e.g., sildenafil) and high-dose calcium channel blockers 
(e.g., amlodipine) are the most common prescribed drug, 
with the latter two at least available in some LIMC. In most 
regions of the world, drugs used to manage all forms of PH 
remain those for the management of heart failure including 
diuretics, calcium channel blockers, angiotensin-converting-
enzyme (ACE) inhibitor, angiotensin II receptor blockers 
(ARB), beta blockers, digitalis, and anti-coagulants (3,41). 
Conclusions
PH is a common clinical syndrome in SSA and other 
LMICs and many of the identified risk factors for PH 
are hyperendemic in those regions. These include LHD, 
lung disease & TB, rheumatic heart disease, HIV and 
schistosomiasis. The intersection of communicable and 
non-communicable diseases in SSA with, generally, late 
presenting patients of the two entities contributing to 
a broad range of PH in the region. Pathways leading to 
PH need to be identified early and managed accordingly. 
Treatment options are limited often to heart failure 
management .  More  comprehens ive  da ta  on  the 
epidemiology of PH from LMICs is desperately needed to 
plan for health interventions and the previously described 
algorithm to diagnose PH in LMICs needs to be validated 
as a screening tool for PH.
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Figure 4 Proposed diagnostic algorithm for the diagnosis of PH-LHD in low-resource settings. PH, pulmonary hypertension; ECG, 
electrocardiography; TB, tuberculosis; PCP, pneumocystis pneumonia; COPD, chronic obstructive pulmonary disease; LHD, left heart 
disease; doppler echo, doppler echocardiography; HIV, human immunodeficiency virus; US, ultrasound; LFT, liver function tests; 
HRCT, high-resolution computerized tomography; CTEPH, chronic thromboembolic pulmonary hypertension; CTPA, CT pulmonary 
angiography; V/Q, ventilation/perfusion lung scan.
Signs, symptoms, medical history and risk factors suggestive of PH
Tricuspid regurge , RVSP >35 mmHg, RA and RV dilatation
Clinical assessment suggestive of PH
Step 2: Basic diagnostic workup
Step 3: Echocardiography
Step 4: Classification of PH
Chest X-ray and ECG suggestive of PH
Step 1: Clinical assessment
Differential diagnoses:
• Tuberculosis
• Pneumocystis pneumonia
• COPD
• Left heart disease
• Cancer
Group 1
Pulmonary arterial 
hypertension (PAH)
Test for HIV, 
schistosomiasis, 
congenital heart disease, 
connective tissue 
disease, drugs and toxins
Group 2
PH due to left heart 
disease
Echo features of systolic 
and diastolic dysfunction, 
valvular disease including 
RHD
Group 3
PH due to lung disease & 
hypoxia
COPD, post-TB and 
interstitial lung disease, 
do liver function tests 
and HRCT
Group 4
Chronic thrombo-
embolic pulmonary 
hypertension (CTEPH)
CTPA
V/Q scan
Group 5
Multifactorial cause of 
PH
Endomyocardial fibrosis
Sickle cell disease
Yes
No
No
No
Yes
Yes
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